Access cutting-edge sickle cell disease treatment through this clinical trial at a research site in Washington Dc. Study-provided care at no cost to qualified participants.
Access sickle cell disease specialists in Washington Dc at no cost
This study follows strict safety protocols and ethical guidelines
All study-related sickle cell disease treatment provided free
The main purpose of this study is to compare the effect of tebapivat versus placebo on anemia and to detect a dose-response for hemoglobin (Hb) response in participants with SCD.
Sponsor: Agios Pharmaceuticals, Inc.
Check if you qualify for this sickle cell disease clinical trial in Washington Dc, DC
If you're searching for sickle cell disease treatment options in Washington Dc, DC, this clinical trial may be an excellent opportunity. Clinical trials provide access to cutting-edge treatments that aren't yet available to the general public, often at no cost to participants.
Our Washington Dc research site is actively enrolling participants for this clinical trial. You'll receive care from experienced sickle cell disease specialists who are at the forefront of medical research. All study-related care, including examinations, treatments, and monitoring, is provided at no cost to qualified participants.